Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 12/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19301631 | 0.85 | KDM4E (0.40) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL18403236 | 0.81 | MAP3K12 (0.41) | PLATGABRA1GABRB2 | |
| SCHEMBL15890096 | 0.81 | HRH4 (0.37) | PLATALDH1A1PDE7AHRH4 | |
| SCHEMBL18403284 | 0.79 | MAP3K12 (0.42) | PLAT | |
| SCHEMBL18403301 | 0.77 | PLAT (0.43) | PLATGABRA1GABRB2 | |
| SCHEMBL18403300 | 0.76 | MAP3K12 (0.55) | — | |
| SCHEMBL2852441 | 0.75 | MEN1 (0.46) | ALDH1A1GABRA1GABRB2NSD3 | |
| SCHEMBL19938695 | 0.73 | MAP3K12 (0.51) | PLATGABRA1GABRB2 | |
| SCHEMBL4232850 | 0.73 | PLAT (0.41) | PLATGABRA1GABRB2 | |
| SCHEMBL4774418 | 0.73 | SMYD3 (0.44) | PLATGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10028942-B2 | 3-substituted pyrazoles and uses thereof | GENENTECH, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| EP-2945938-B1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2018-03-07 | — | — | EP | disclosed |
| US-20170087137-A1 | 3-SUBSTITUTED PYRAZOLES AND USES THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9550777-B2 | 3-substituted pyrazoles and use as DLK inhibitors | GENENTECH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170087137-A1 | 3-SUBSTITUTED PYRAZOLES AND USES THEREOF | PDXK, NLK, PDK3 | PLAT 3498/4885KDM4E 732/4885ALDH1A1 579/4885 |
| US-10028942-B2 | 3-substituted pyrazoles and uses thereof | PDXK, NLK, PDK3 | PLAT 3498/4885KDM4E 732/4885ALDH1A1 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.